MetaCap

BriaCell Therapeutics (BCTX) vs Edesa Biotech (EDSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed BriaCell Therapeutics (BCTX) over the past year, gaining 17.6% versus a loss of 61.7%. Over five years, EDSA leads with a -95.6% price change compared with -97.0% for BCTX. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCTX-61.75%EDSA+17.65%
+1027%+455%-118%
Nov 21, 20251 yearNov 20, 2026
BCTX-97.12%EDSA-95.72%
+18%-43%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCTX versus EDSA key metrics
MetricBCTXEDSA
Share price$3.06$2.00
Market cap$26.72M$27.02M
1-day change-3.32%-8.05%
YTD return-56.96%+40.85%
1-year return-61.75%+17.65%
5-year return-97.00%-95.63%
EPS (TTM)$-6.97$-1.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.90M$-7.19M
52-week high$13.09$20.32
52-week low$2.60$0.72
Distance from 52-week high-76.62%-90.16%
Analyst consensus—none
Avg. price target upside—+716.50%
Average volume250.81K1.45M
Shares outstanding8.73M13.51M
Employees—17
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed BCTX by 79.4 percentage points over the past year.

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

BCTX vs EDSA FAQ

Which is bigger, BriaCell Therapeutics or Edesa Biotech?

Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, BCTX or EDSA?

EDSA returned +17.65% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.

Are BriaCell Therapeutics and Edesa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons